Entrar Registro gratuito

Last updated: 31 March 2023 at 4:15pm EST

Michael T. Constantino Net Worth




The estimated Net Worth of Michael T. Constantino is at least $4.24 mil dollars as of 23 May 2022. Michael Constantino owns over 16,000 units of 9 Meters Biopharma stock worth over $4,236 and over the last 4 years Michael sold NMTR stock worth over $0.

Michael Constantino NMTR stock SEC Form 4 insiders trading

Michael has made over 3 trades of the 9 Meters Biopharma stock since 2020, according to the Form 4 filled with the SEC. Most recently Michael bought 16,000 units of NMTR stock worth $7,680 on 23 May 2022.

The largest trade Michael's ever made was buying 34,108 units of 9 Meters Biopharma stock on 20 August 2020 worth over $25,581. On average, Michael trades about 9,730 units every 92 days since 2020. As of 23 May 2022 Michael still owns at least 60,508 units of 9 Meters Biopharma stock.

You can see the complete history of Michael Constantino stock trades at the bottom of the page.



What's Michael Constantino's mailing address?

Michael's mailing address filed with the SEC is C/O 9 METERS BIOPHARMA, INC., 4509 CREEDMOOR ROAD, SUITE 201, RALEIGH, NC, 27612.

Insiders trading at 9 Meters Biopharma

Over the last 5 years, insiders at 9 Meters Biopharma have traded over $20,934,964 worth of 9 Meters Biopharma stock and bought 2,247,050 units worth $1,572,701 . The most active insiders traders include Israel Gp Ltd.Orbi Med Isra..., Mark A Sirgo, eJohn Temperato. On average, 9 Meters Biopharma executives and independent directors trade stock every 35 days with the average trade being worth of $45,283. The most recent stock trade was executed by Bethany Sensenig on 21 April 2023, trading 9,100 units of NMTR stock currently worth $11,011.



What does 9 Meters Biopharma do?

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.



What does 9 Meters Biopharma's logo look like?

9 Meters Biopharma, Inc. logo

Complete history of Michael Constantino stock trades at 9 Meters Biopharma

Data
#
Companhia
 Acionista maioritário
Trans.
Transação
 Ações Preço por ação Preço total Ações após Fonte
23 May 2022 NMTR 9 Meters Biopharma, Inc. Michael T. Constantino
Diretor
 Comprar 16,000 $0.48 $7,680
23 May 2022
60,508 ↗
24 Aug 2021 NMTR 9 Meters Biopharma, Inc. Michael T. Constantino
Diretor
 Comprar 18,000 $1.14 $20,520
24 Aug 2021
52,108 ↗
20 Aug 2020 NMTR 9 Meters Biopharma, Inc. Michael T. Constantino
Diretor
 Comprar 34,108 $0.75 $25,581
20 Aug 2020
34,108 ↗


9 Meters Biopharma executives and stock owners

9 Meters Biopharma executives and other stock owners filed with the SEC include: